Implementation Strategies for Monitoring Adherence in Real Time

NAActive, not recruitingINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

February 22, 2021

Primary Completion Date

November 30, 2022

Study Completion Date

October 20, 2025

Conditions
Lung CancerMedication AdherenceSymptoms and Signs
Interventions
DEVICE

Conversational Agent/Chatbot

Via text messages, the bidirectional, conversation agent provides specific dosing instructions and motivational reminders to promote oral targeted therapy adherence and symptom management. Patients can report symptoms at any time via text message and are also prompted to report symptoms and medication adherence at periodic intervals. Reported symptoms are monitored and managed algorithmically according severity. High-grade symptoms are triaged directly to the patients' cancer care team. Patients in the intervention arm will use MEMS caps to enable capture of the primary outcome and asked to complete longitudinal surveys.

OTHER

Usual Care

Patients in the control arm will receive usual care, which includes receiving information about dosing and self-administration of oral therapy, and anticipatory guidance for patients regarding management of side effects. Patients in the control arm will use MEMS caps to enable capture of the primary outcome and asked to complete longitudinal surveys.

Trial Locations (1)

19104

University of Pennsylvania, Philadelphia

Sponsors
All Listed Sponsors
collaborator

Lung Cancer Research Foundation

OTHER

collaborator

Pfizer

INDUSTRY

lead

Abramson Cancer Center at Penn Medicine

OTHER